Do guidelines for treating chest disease in children use Cochrane reviews effectively?
Prayle, Andrew; Cox, Tessy; Smith, Sherie J.; Rycroft-Malone, Joanne; Thomas, Kim S.; Hughes, Dyfrig; Smyth, Alan R.
Thorax

DOI:
10.1136/thoraxjnl-2016-208790

Published: 01/07/2018

Peer reviewed version

Cyswllt i'r cyhoeddiad / Link to publication

Dyfyniad o’r fersiwn a gyhoeddwyd / Citation for published version (APA):

Hawliau Cyffredinol / General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Do guidelines for treating chest disease in children use Cochrane reviews effectively? A systematic review.

Authors:

Andrew P Prayle1, Tessy Cox1, Sherie J Smith1, Joanne Rycroft-Malone2, Kim S Thomas3, Dyfrig A Hughes4, Alan R Smyth1

1. Division of Child Health, Obstetrics and Gynaecology, University of Nottingham.
2. School of Healthcare Sciences, Bangor University
3. Centre of Evidence Based Dermatology, University of Nottingham
4. Centre for Health Economics and Medicines Evaluation, Bangor University

Copyright / license for publication:

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non-exclusive licence for UK Crown and US Federal Government employees) on a worldwide basis to the BMJ Publishing Group Ltd, and its Licensees to permit this article (if accepted) to be published in Thorax and any other BMJPGL products and to exploit all subsidiary rights, as set out in our licence.

Competing interests:

All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work. Prof Smyth reports personal fees from Vertex, personal fees from Gilead, personal fees from Roche, personal fees from PTC Therapeutics, outside the submitted work. In addition, Prof Smyth has a patent ALKYL QUINOLONES AS BIOMARKERS OF PSEUDOMONAS AERUGINOSA INFECTION AND USES THEREOF issued.

Transparency Declaration:

The lead author affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

Contributorship:
The study was conceived by ARS, with development by APP and TC. Final study design was achieved by discussion of all authors. Data collection: TC, APP and SS. Data analysis, statistics and programming: APP. Final manuscript written and approved by all authors.

**Ethical approval:**

Not required.

**Acknowledgements**

The authors thank all those who were involved in the development and authorship of the Cochrane Reviews and Guidelines used within this study.

**Funding sources.**

This work did not receive specific funding. APP was funded by a NIHR Doctoral Research Fellowship (DRF-2009-02-112), and is currently funded by a NIHR ACL post. Dyfrig Hughes receives financial support from the MRC North West Hub in Trial Methodological Research: MR/K025635/1. The funders and sponsor had no involvement in the decision to publish, or the contents of the publication. This report presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

**Data sharing**

The raw data and computer code underlying this study to fully reproduce all the statistics and figures reported are available as a downloadable supplementary file on DataDryad <insert link when available>.

**PRISMA statement**

The study’s PRISMA Statement is available as a supplementary file.

**Word Counts:**

Abstract: 99

Text:
ABSTRACT
Cochrane Reviews summarise best evidence and should inform guidelines. We assessed the use of Cochrane Reviews in UK guidelines for paediatric respiratory disease. We found 21 guidelines which made 1025 recommendations, of which 96 could be informed by a Cochrane Review. In 38/96 recommendations (40%), some or all of the relevant Cochrane Reviews were not cited. We linked recommendations to 140 Cochrane Reviews. In 37/140 (26%) cases, the guideline recommendation did not fully agree with the Cochrane Review. Guideline developers may fail to use Cochrane Reviews or may make recommendations which are not in line with best evidence.
INTRODUCTION

Clinical practice guidelines support optimal decision making in medical care. Guidelines should use the best available evidence (1). Systematic reviews use transparent criteria (such as GRADE) to evaluate the quality of evidence (2) and so systematic reviews (where available) should be the primary source of evidence in guidelines. The Cochrane Collaboration produces systematic reviews (‘Cochrane Reviews’) using a rigorous methodology. These are peer reviewed at the protocol and review stage, and are updated regularly (3). Previous work indicates that guidelines do not make full use of Cochrane Reviews (4, 5). This represents research wastage, and may lead to suboptimal medical care.

Respiratory disease in children is common - 20% of children visiting the emergency department, with a medical problem, will have a respiratory illness (6). However, the paediatric respiratory evidence base is limited. Nearly half of children with respiratory disease receive a medication which is off-label or unlicensed (7). It is particularly important that guidelines for respiratory disease in children make the best use of this limited evidence. We examined the use of evidence from Cochrane Reviews in guidelines for respiratory disease in children.

We aimed to understand the use of the best available evidence in the field of paediatric respiratory medicine. We systematically examined the use of Cochrane Reviews in UK clinical guidelines for lower respiratory diseases in children and we examined the agreement between the guideline recommendations and the Cochrane Reviews. We investigated the association between guideline commissioning agency, the topic, the publication year and the use of alternate high quality evidence upon whether Cochrane Reviews were cited, and whether their conclusions were followed.

METHODS

We identified all the respiratory guidelines in the UK for lower respiratory tract disease for children via database and web searches. We simultaneously identified all the Cochrane reviews relevant to paediatric respiratory medicine, via the Cochrane library. For each guideline, we included all recommendations pertaining to an intervention for lower respiratory tract disease in children. For each recommendation, we identified if there was a Cochrane review which could inform it, and which had been published at least one year prior to the guideline. We mapped each guideline recommendation to relevant Cochrane reviews.
For each linked guideline recommendation – Cochrane review, we categorized the agreement between the guideline recommendation and the Cochrane review into one of four categories: (i) totally, (ii) partially, (iii) not in agreement, or (iv) a strong guideline recommendation where the Cochrane review concluded that there was not enough evidence to draw a conclusion (see Supplementary information file 1 for definitions and examples). Where guideline recommendations disagreed with the Cochrane review, we categorized the extent of the disagreement. The protocol (including study eligibility criteria and statistical analysis plan) was produced in advance of the data collection, is available at the University of Nottingham ePrints server and as supplementary files 2 and 3). Detailed methods are provided in Supplementary Information.

RESULTS

Guidelines and Cochrane Reviews identified

We included 21 guidelines and 236 Cochrane Reviews (see Figure 1). The 21 guidelines made 1025 recommendations of which 555 were for treatment of lower respiratory disease in children. We identified relevant Cochrane Reviews for 96 (17.3%) of these 555 recommendations.

Of the 96 recommendations that could use Cochrane Reviews, 28/96 (29%) did not use any, and 10/96 (10%) did not use all the available Cochrane Reviews. There were 140 instances where a Cochrane Review could be linked to at least one guideline recommendation. Of these 103/140 (74%) were in agreement, 13/140 (9%) were partially in agreement, 5/140 (4%) disagreed and 19 / 140 (13%) were strong recommendations but the Cochrane Review did not draw a conclusion. Few Cochrane Reviews in paediatric respiratory medicine are able draw a strong conclusion, 96/283 (34%).

We summarise these data in Figure 2. An on-line interactive version of this figure allowing the reader to directly explore the data within a web browser is available at <insert link>, and can be downloaded directly from <inset link>.

Further analysis is presented in the online supplement, including a sensitivity analysis of our judgements in categorizing agreement and an analysis investigating the impact of commissioning agency, guideline topic, guideline year and guideline use of alternate high quality evidence on the use of Cochrane reviews.

DISCUSSION
We found that 38/96 (40\%) of guideline recommendations did not use all the relevant Cochrane Reviews. The majority of guideline recommendations were in agreement with Cochrane Review recommendations. We present the data as an interactive figure allowing the reader to explore the links between Cochrane Reviews and guideline recommendations.

Our results are broadly in keeping with studies in other fields such as smoking cessation and neonatal medicine which show that guidelines do not make the best use of Cochrane Reviews. Silagy et al (4) found four guidelines for smoking cessation (one from the UK). In the UK guideline 16/22 recommendations could have cited a Cochrane Review but only 8 recommendations did so. Brok et al (5) studied the agreement between guidelines and Cochrane Reviews for new-borns in Denmark. Compared to our study, they found similar discrepancies between Cochrane Reviews and guideline recommendations - 24\% were not in agreement (of which 6\% partially agreed, and 18\% disagreed).

Our study is comprehensive, used an a priori protocol, and categorizations were conducted independently by two investigators. The study has limitations, including the subjectivity in decisions regarding agreement and disagreement. We expand on this in supplementary file 2.

**Conclusion**

In spite of the work of the Cochrane collaboration, there are still many treatment decisions where there is no systematic review to inform guideline recommendations. However, we have shown that, even where a Cochrane Reviews exists, guideline developers may not make use of it or may make recommendations contrary to the findings of the review. This study demonstrates that only a minority of recommendations in clinical practice guidelines are based on the highest quality evidence. A great deal of money, time and effort goes into creating and updating Cochrane Reviews. Not using such evidence in guidelines constitutes research waste.
Figure 1. Flow diagram of the selection of guidelines and Cochrane Reviews
Figure 2. Do Cochrane Reviews influence clinical practice guideline recommendations? Evidence network diagram to show the links between Cochrane Reviews and Guideline recommendations. Each individual guideline recommendation is represented by a purple node, and each Cochrane review by a green node. A solid blue line connecting a guideline recommendation to a Cochrane recommendation indicates that the guideline cited the Cochrane Review, and the two are in agreement. A broken line indicates that the guideline did not cite the Cochrane Review. A brown line indicates that the Cochrane Review and guideline were not totally in agreement. Panel A shows all the links. Subsequent panels are sub-grouped by disease topic: B = asthma, C = cystic fibrosis, D = respiratory infections and E = respiratory aspects of critical care. An interactive web based version of the evidence network diagram (which loads in all recent major browsers) is available at <insert hyperlink>, and allows the reader to explore the underlying data further.
REFERENCES


